A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

Camryn was diagnosed with a low-grade glioma at age two after her parents noticed a lazy eye. Sixteen years, 11 brain surgeries and over six years of chemotherapy treatment, Camryn is now ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Improving Oncotype DX turnaround time for timeliness of adjuvant therapy: A single-system, multi-site quality improvement study in early-stage HR-positive breast cancer. This is an ASCO Meeting ...

Targeted therapy and immunotherapy have transformed cancer treatment, but they work in very different ways. A medical ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...